Ganciclovir

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 43, Issue , 2018, Pages 1-208

  Al Badr, Abdullah A ^a   Ajarim, Tariq D S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cytomegalovirus; Description; Ganciclovir; Metabolism; Methods of analysis; Nomenclature; Pharmacokinetics; Physical characteristics; Reviews; Spectral properties; Stability; Synthesis; Uses

Indexed keywords

GANCICLOVIR; ANTIVIRUS AGENT;

CHEMOLUMINESCENCE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG METABOLISM; DRUG NOMENCLATURE; DRUG SOLUBILITY; DRUG STABILITY; ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IONIZATION; NONHUMAN; PARTITION COEFFICIENT; POTENTIOMETRY; RADIOIMMUNOASSAY; SPECTROPHOTOMETRY; SPECTROSCOPY; TANDEM MASS SPECTROMETRY; THERMAL ANALYSIS; X RAY ANALYSIS; ANIMAL; BIOAVAILABILITY; BIOTRANSFORMATION; CHEMISTRY; PHARMACEUTICS; PROCEDURES;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DRUG COMPOUNDING; DRUG STABILITY; GANCICLOVIR; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 85044153784     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.podrm.2017.12.001     Document Type: Chapter

References (315)

1. O'Neil, M.J., (eds.) The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals, 14th ed., 2006, Merck and Co., Inc., Whitehouse Station, NJ, 380 Monograph 2282.
2. Sweetman, S.C., (eds.) Martindale: The Complete Drug Reference, 37th ed., 2009, Pharmaceutical Press, London Electronic version.
3. Moffat, A.C., (eds.) Clarke's Isolation and Identification of Drugs, second ed., 1989, The Pharmaceutical Press, London.
4. Faulds, D., Heel, R.C., Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39 (1990), 597–638.
5. Markham, A., Faulds, D., Ganciclovir: an update of its therapeutic use in cytomegalovirus infections. Drugs 48 (1994), 455–484.
6. Crumpacker, C.S., Ganciclovir: a review. N. Engl. J. Med. 335 (1996), 721–729.
7. McGavin, J.K., Gao, K.I., Ganciclovir: an update of its use in the prevention of cytomegalovirus infections and disease in transplant recipients. Drugs 61 (2001), 1153–1183.
8. Field, A.K., Davies, M.E., DeWitt, C., Perry, H.C., Liou, R., Germershausen, J., Karkas, J.D., Ashton, W.T., Johnston, D.B., Tolman, R.L., 9-[(2-Hydroxy)-1-(hydroxymetyyl)ethoxy]methyl guanine: as selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. U. S. A. 80 (1983), 4139–4143.
9. Ashton, W.C., Karleas, J.D., Field, A.K., Tolman, R.L., Activation of thymidine kinase and potent activity of 2′-nor-2′-deoxyguanosine (2′-NDG). Biochem. Biophys. Res. Commun. 108 (1982), 1716–1721.
10. Ogilvie, K.K., Cheriyan, U.O., Radatus, B.K., Biologically active acyclonucleoside analogues, II. The synthesis of 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (BIOLF-62). Can. J. Chem. 60 (1982), 3005–3010.
11. Martin, J.C., Dvorak, C.A., Smee, D.F., Matthews, T.R., Verheyden, J.P.H., 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J. Med. Chem. 26 (1983), 759–761.
12. Ogilvie, K.K., Nguyen-Ba, N., Gillen, M.F., Radatus, B.K., Cheriyan, U.O., Hanna, H.R., Synthesis of a purine acyclonucleoside series having pronounced antiviral activity. The glyceropurines. Can. J. Chem. 62 (1984), 241–252.
13. 2,9-diacetylquanine with sulfinylmether ether. Synth. Commun. 18 (1988), 1651–1660.
14. Hakimelahi, G.H., Khalafi-Nezhad, A., Catalytic effect of tetrabutyl ammonium fluoride in the preparation of seco-ribo nucleosides. Helv. Chim. Acta 72 (1989), 1495–1500.
15. Alhede, B., Clausen, F.P., Juhl-Christensen, J., McCluskey, K.K., Preikschat, H.F., A simple and efficient synthesis of 9-substituted guanines. Cyclodesulfurization of 1-substituted 5-[(thiocarbamoyl)amino] imidazole-4-carboxamide under aqueous basic conditions. J. Org. Chem. 56 (1991), 2139–2143.
16. Kim, D.K., Kim, H.K., Choe, Y.-B., Design and synthesis of 6-fluoropurine acyclonucleosides: potential prodrugs of acyclovir and ganciclovir. Bioorg. Med. Chem. Lett. 4 (1994), 1309–1312.
17. Boryski, J., Golankiewicz, B., A facile synthesis of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) from guanosine. Synthesis 4 (1999), 625–628.
18. Sariri, R., Khalili, G., A novel approach to the synthesis of the purine anti-viral agent ganciclovir. Indian J. Chem. 42 (2003), 651–654.
19. Raju, V.V.N.K.V.P., Ravindra, V., Kamath, S.S., Mathad, V.T., Dubey, P.K., Reddy, P.P., A facile synthesis of potent antiherpes drug substance, ganciclovir, 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine, using a new masked glycerol derivative. Arkivoc 12 (2009), 296–301.
20. Kawamura, T., Hirayama, N., X-ray Structure Analysis Online. Crystal structure of ganciclovir, vol. 25, 2009, 51–52.
21. Noble, S., Faulds, D., Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56 (1998), 115–146.
22. CrystalStructure, version 3.5.1, Crystal Structure Analysis Package, Rigaku and Rigaku/MSC. 2000–2003.
23. Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M., Polidori, G., Camalli, M., SIRPOW.92: a program for automatic solution of crystal structures by direct methods optimized for powder data. J. Appl. Cryst. 27 (1994), 435–443.
24. Farrugia, L.J., ORTEP III. J. Appl. Cryst., 22, 1997, 389.
25. Thewalt, U., Bugg, C.E., Marsh, R.E., The crystal structure of guanosine dihydrate and inosine dehydrate. Acta Crystallogr. B 26 (1970), 1089–1101.
26. Sarbajna, R.M., Preetam, A., Devi, A.S., Suryanarayana, M.V., Sethi, M., Dutta, D., Studies on crystal modifications of ganciclovir. Mol. Cryst. Liq. Cryst. 537 (2011), 141–154.
27. United States Pharmacopeia, National Formulary. USP 29-NF 24, 2006.
28. Chan, T.W., Nguyen, H.T., Anhydrous crystalline 9-(1,3-diydroxy-2-propoxymethyl)guanine. U.S. patent application number 4,642,346, 1987, Assignee Syntex (USA) Inc.
29. Heleblian, J.K., McCrone, W., Pharmaceutical application of polymorphism. J. Pharm. Sci. 58 (1969), 911–929.
30. Heleblian, J.K., Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci. 64 (1975), 1269–1288.
31. Byrn, S.R., Pfeiffer, R.R., Stowell, J.G., Solid-State Chemistry of Drugs. 1999, SSCI Inc., West Lafayette, IN.
32. Snider, D.A., Addicks, W., Owens, W., Polymorphism in generic drug product development. Adv. Drug Deliv. Rev. 56 (2004), 391–395.
33. ICH Guidance on Q6A Specs, Test procedures and acceptance criteria for new drug substances and new drug products: chemical-subtances. Fed. Regist., 65, 2000, 83041.
34. Silverstein, R.M., Webster, F.X., Kiemle, D.J., Bryce, D.L., Spectrometric Identification of Organic Compounds. eighth ed., 1999, Wiley, India.
35. Eddy, C.V., Arnold, M.A., Near-infrared spectroscopy for measuring urea in hemodialysis fluids. Clin. Chem. 47 (2001), 1279–1286.
36. Ciurczak, E.W., Igne, B., Pharmaceutical and Medical Applications of Near-Infrared Spectroscopy. 2002, Marcel Dekker Inc., USA.
37. Westad, F., Schmidt, A., Kermit, M., Incorporating chemical bond-assignment in near-infrared spectroscopy regression models. J. Near Infrared Spectrosc. 16 (2008), 265–273.
38. Burger, A., Ramberger, R., On the polymorphism of pharmaceuticals and other molecular crystals. Microchim. Acta. 72 (1979), 259–271 273–316.
39. Morris, K.R., Structural aspects of hydrates and solvents. Brittain, H.G., (eds.) Polymorphism in Pharmaceutical Solids, 95, 1999, Marcel Dekker, New York, 125–181.
40. Redman-Furey, N., Dicks, M., Godlweski, J., Vaughn, D., Collins, O., The role of TGA-DTA in the initial evaluation of the solids state forms for pharmaceutical new chemical entities, part 1: evaluation of pure forms. J. ASTM Int. 2 (2005), 1–10.
41. Redman-Furey, N., Dicks, M., Godlweski, J., Vaughn, D., Collins, O., The role of TGA-DTA in the initial evaluation of the solids state forms for pharmaceutical new chemical entities, part 2: evaluation of mixed forms. J. ASTM Int. 2 (2005), 1–9.
42. Pan, W.-P., Judovits, L., (eds.) Techniques in Thermal Analysis: Hyphenated Techniques, Thermal Analysis of the Surface and Fast Rate Analysis, 2007, ASTM International Standards Worldwide, PA, USA.
43. Fernandes, J.A., Galli, S., Palmisano, G., Volante, P., Mendes, R.F., Paz, F.A.A., Masciocchi, N., Reviewing the manifold aspects of ganciclovir crystal forms. Cryst. Growth Des. 16 (2016), 4108–4118.
44. Wilhelmus, K.R., Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst. Rev.(1), 2015, CD002898.
45. Bernstein, J., Polymorphism—a perspective. Cryst. Growth Des. 11 (2011), 632–650.
46. Brittain, H.G., Polymorphism in Pharmaceutical Solids. 2009, Informa Healthcare, New York.
47. Bernstein, J., Polymorphism in Molecular Crystals. 2007, International Union of Crystallography, Oxford.
48. Hilfiker, R., (eds.) Polymorphism: In the Pharmaceutical Industry, 2006, Wiley-VCH, Weinheim.
49. Desiraju, G.R., Crystal engineering: a brief overview. J. Chem. Sci. 122 (2010), 667–675.
50. Cabri, W., Ghetti, P., Pozzi, G., Alpegiani, M., Polymorphisms and patent, market, and legal battles: cefdinir case study. Org. Process Res. Dev. 11 (2007), 64–72.
51. Bernstein, J., Polymorphism and patents from a chemist's point of view [1]. Hilfiker, R., (eds.) Polymorphism: In the Pharmaceutical Industry, 2006, Wiley-VCH, Weinhem, 365–384.
52. Cruz-Cabeza, A.J., Reutzel-Edens, S.M., Bernstein, J., Facts and fiction about polymorphism. J. Chem. Soc. Rev. 44 (2015), 8619–8635.
53. Griesser, U.J., The importance of solvates. Hilfiker, R., (eds.) Polymorphism: In the Pharmaceutical Industry, 2006, Wiley-VCH, Weinheim, 211–233.
54. Verheyden, J.P., Martin, J.C., 9-(1,3-Dihydroxy-2-propoxymethyl)-guanine as antiviral agent. US4355032, 1982.
55. Flores, R.L.R., Ávila, S.G., Oliveira, J.F., Carvalho, F.M.S., Araújo, G.L.B., Matos, J.R., In Caracterização Fisico-Quı´mica e Analı´tica do Ganciclovir. 2014, Abratec, Serra Negra.
56. Parthasaradhi, R.B., Rathnakar, R.K., Muralidhara, R.D., Raji, R.R., Vamsi, K.B., Subash, C.R.K., Venkata, R.R.I., Process for the isolation of ganciclovir intermediate. WO20111114336A1, 2011.
57. Salari, A., Young, R.E., Application of automated total reflectance FTIR spectroscopy to the analysis of mixtures of pharmaceutical polymorphs. Int. J. Pharm. 163 (1998), 157–166.
58. Mao, W., Wu, P., Unhydrous crystal form of ganciclovir sodium and preparation method thereof. CN 103570716, 2013.
59. Mao, W., Wu, P., Zhang, Q., Cui, J., Crystal type ganciclovir sodium hydrate and preparing method thereof. CN 103524505, 2014.
60. Volante, P., Michelini, P., Ganciclovir sodium salt in crystalline form. WO/111049, 2003, A1.
61. Fernandes, J.A., Sardo, M., Mafra, L., Choquesillo-Lazarte, D., Masciocchi, N., X-ray and NMR crystallography studies of novel theophylline cocrystals prepared by liquid assisted gringing. Cryst. Growth Des. 15 (2015), 3674–3683.
62. Vladiskovic, C., Masciocchi, N., Reversibly changing a painkiller structure: a hot topic for cold case—ibuprofen lysine salt. J. Pharm. Biomed. Anal. 107 (2015), 394–402.
63. Giacobbe, C., Palmisano, G., Giovenzana, G.B., Giovannelli, L., Negri, R., Masciocchi, N., Difluprednate, more than meets the eye. J. Pharm. Biomed. Anal. 102 (2015), 305–313.
64. Vladiskovic, C., Masciocchi, N., Persistency of a two-fold embrace in crystalline phases of bupropion hydrochloride: a thorough ab initio X-ray powder diffraction study. Cryst. Growth Des. 14 (2014), 3603–3611.
65. Vladiskovic, C., Masciocchi, N., Cervellino, A., A structural powder diffraction study of two polymorphic forms of nortriptyline hydrochloride. J. Pharm. Sci. 101 (2012), 4481–4489.
66. Barrio, M., Maccaroni, E., Rietveld, I.B., Malpezzi, L., Masciocchi, N., Céolin, R., Tamarit, J., Pressure-temperature state diagram for the phase relationships between benfluorex hydrochloride forms I and II: a case of enantiotropic behavior. J. Pharm. Sci. 101 (2012), 1073–1078.
67. Maccaroni, E., Giovenzana, G.B., Palmisano, G., Botta, D., Volante, P., Masciocchi, N., Structures from powders: diflorasone diacetate. Steroids 74 (2009), 102–111.
68. Moreno-Calvo, E., Muntó M., Wurst, K., Ventosa, N., Masciocchi, N., Veciana, J., Polymorphs and solvates of nicardipine hydrochloride. Selective stabilization of different diastereomeric racemates. Mol. Pharm. 8 (2011), 395–404.
69. Colombo, V., Masciocchi, N., Palmisano, G., Crystal chemistry of the antibiotic doripenem. J. Pharm. Sci. 103 (2014), 3641–3647.
70. Kottke, T., Stalke, D., Crystal handling at low temperature. J. Appl. Cryst. 26 (1993), 615–619.
71. APEX2, Data Collection Software, Version 21-RC13. 2006, Bruker AXS, Delft.
72. SAINT. Data Integration Engine v 723a; Bruker AXS: Madison, WI.
73. Sheldrick, G.M., SADABS v 201, Bruker/Siemens Area Detector Absorption Correction Program. 1998, Bruker AXS, Madison, WI.
74. Sheldrick, G.M., A short history of SHELX. Acta Crystallogr. A 64 (2008), 112–122.
75. Sheldrick, G.M., Crystal structure refinement with SHELXL. Acta Crystallogr. C 71 (2015), 3–8.
76. Coelho, A.A., Indexing of powder diffraction patterns by iterative use of singular value decomposition. J. Appl. Cryst. 36 (2003), 86–95.
77. TOPAS-R, Version 3.0, 2005, Bruker, Karlsruhe, Germany.
78. Kleywegt, G.J., Jones, T.A., Databases in protein crystallography. Acta Crystallogr. D 54 (1998), 1119–1131.
79. a values of guanine in water: density functional theory calculations combined with Poisson-Boltzmann continuum-solvation model. J. Phys. Chem. B 107 (2003), 344–357.
80. Cheary, R.W., Coelho, A., A fundamental parameters approach to X-ray line-profile fitting. J. Appl. Cryst. 25 (1992), 109–121.
81. March, A., Mathematische theorie der regelung nach der korngestah bei affiner deformation. Z. Kristallogr. Cryst. Mater. 81 (1932), 285–297.
82. Dollase, W.A., Correction of intensities for preferred orientation in powder diffractometry: application of the March model. J. Appl. Cryst. 19 (1986), 267–272.
83. When comparing the TGA and VT-PXRD results, the reader must be aware that the thermocouple of the VT-PXRD setup is not in direct contact with the sample, this determining a slight difference in the temperature at which the same event is detected by the two techniques. The TGA temperatures have to be considered more reliable.
84. 3. Because of the paucity of peak position maxima in ref. [23], we cannot suggest a tentative unit cell for the hydrated monosodium salt.
85. The labels of the atoms reported in ref. [20] have been changed in order to allow direct comparison with the results presented in this work.
86. Grell, J., Bernstein, J., Tinhofer, G., Graph-set analysis of hydrogen bond patterns: some mathematical concepts. Erratum Acta Crystallogr. B 55 (1999), 1030–1043.
87. The existence of hydrogen-bonded chains along the b-axis and π–π stacking along the c-axis, vs water molecules-mediated hydrogen bond interactions between the chains along the a-axis, might concur to explain the existence of preferred orientation along the (100) direction.
88. Macrae, C.F., Edgington, P.R., McCabe, P., Pidcock, E., Shields, G.P., Taylor, M., Towler, M., van de Streek, J., Mercury: visualization and analysis of crystal structures. J. Appl. Cryst. 39 (2006), 453–457.
89. Martin, J.C., Tippie, M.A., McGee, D.P., Verheyden, J.P., Synthesis and antiviral activity of various esters of 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine. J. Pharm. Sci. 76 (1987), 180–184.
90. Jiang, H., Zhang, H., Xie, F.-p., Determination of ganciclovir by acid chrome blue K fading spectrophotometry. Huaxue Shiji 31 (2009), 441–443.
91. Jiang, H., Liu, J.-b., Yin, H.-l., Spectrophotometric determination of ganciclovir with Evans blue as color reagent. Lihua Jianyan, Huaxue Fence 45 (2009), 740–741.
92. Gouda, A.A., Utility of certain sigma- and pi-acceptors for the spectrophotometric determination of ganciclovir in pharmaceutical formulations. Talanta 80 (2009), 151–157.
93. Sarsambi, P.S., Sonawane, A., Malipatil, S.M., Raju, S.A., Application of UV-spectrophotometric methods for the estimation of ganciclovir in bulk drug and its formulations. J. Indian Counc. Chem. 27 (2010), 202–204.
94. Sarsambi, P.S., Sonawane, A., Malipatil, S.M., Hiremath, B., Faheem, A., Spectrophotometric estimation of ganciclovir in bulk drug and its formulation. Int. J. PharmTech Res. 2 (2010), 1264–1268.
95. Sarsambi, P.S., Gowrisankar, D., Sonawane, A., Faheem, A., Visible spectrophotometric determination of ganciclovir by condensation and oxidative coupling reactions. Int. J. PharmTech Res. 2 (2010), 282–285.
96. Gouda, A.A., Amin, A.S., Utility of inorganic oxidants for the spectrophotometric determination of ganciclovir in dosage forms. Lat. Am. J. Pharm. 30 (2011), 334–341.
97. Kumar, T.A., Gurupadayya, B.M., Reddy, M.B.R., Raju, M.V.P., Selective and validated spectrophotometric methods for determination of acyclovir and ganciclovir with 2, 4 DNP as reagent. J. Appl. Chem. Res. 19 (2011), 27–40.
98. Kumar, T.A., Gurupadayya, B.M., Reddy, M.B.R., Selective and validated spectrophotometric methods for determination of ganciclovir with PDAB and Folin's reagents. Indian J. Chem. Technol. 19 (2012), 56–62.
99. AL-Neaimy, U.I., Hamdon, E.A., The use of oxidation reaction for the spectrophotometric determination of ganciclovir in pharmaceutical formulations. Raf. J. Sci. 23 (2012), 93–104.
100. Khairnar, H.K., Oswal, R.J., Kshirsagar, S.S., Chaudhari, P.S., Bayas, J.P., New simple UV spectrophotometric method for determination of ganciclovir in bulk and capsule formulation. Int. J. Res. Pharmaceut. Biomed. Sci. 3 (2012), 439–442.
101. Kumar, T.A., Gurupadayya, B.M., Reddy, M.B.R., Selective and validated spectrophotometric assay for microgram determination of ganciclovir with 1-fluoro-2,4-dinitrobenzene and N-bromosuccinimide reagents. J. Appl. Chem. Res. 20 (2012), 14–27.
102. Khairnar, H.K., Jedge, S.R., Patel, B.D., Kshirsagar, S.S., Oswal, R.J., Second-derivative UV spectrometric determination of ganciclovir in its solid dosage form. Anal. Chem. Indian J. 11 (2012), 260–263.
103. Anil Kumar, T., Gurupadayya, B.M., Rahul Reddy, M.B., Prudhviraju, M.V., Selective and validated spectrophotometric methods for determination of acyclovir and ganciclovir with 2,4 DNPH as reagent. J. Appl. Chem. Res. 6 (2012), 14–24.
104. AL-Neaimy, U.I.S., Spectrophotometric estimation of ganciclovir in pharmaceutical formulations using alizarin sulfonic acid sodium salt reagent. J. Educ. Sci. 26 (2013), 65–73.
105. Madhusudhana, R.G., Babu, C.J.G., Mani, T.T., Validated spectrophotometric estimation of ganciclovir in pure and capsule dosage form. Imp. J. Interdescip. Res. 3 (2017), 368–370.
106. Ramesh, P.J., Basavaiah, K., Xavier, M.C., Prashanth, K.N., Raghu, S.M., Titrimetric and spectrophotometric assay of ganciclovir in pharmaceuticals using cerium(IV) sulphate as the oxidimetric agent. ISRN Anal. Chem., 2012, 2012 8 pages.
107. Reddy, C.M.B., Reddy, G.V.S., Determination of ganciclovir in bulk and pharmaceutical dosage forms by UV spectrophotometric method. Int. Res. J. Pharm. 3 (2012), 286–288.
108. Al-Neaimy, U.I.S., Al-Delymi, A.M.S., Visible spectrophotometric determination of ganciclovir in its pharmaceutical formulations using quinalizarin reagent. Jordan J. Chem. 8 (2013), 103–112.
109. Balwani, G., Joseph, E., Reddi, S., Nagpal, V., Saha, R.N., Rapid, simple, and sensitive spectrofluorimetric method for the estimation of ganciclovir in bulk and pharmaceutical formulations. J. Spectrosc., 2013, 2013, 972806 5 pages.
110. Thomas, O.E., Adegoke, O.A., Development of a visible spectrophotometric method for the analysis of ganciclovir in bulk sample and dosage form. Trop. J. Pharm. Res. 14 (2015), 1095–1101.
111. Uslu, B., Doğan, B., Özkan, S.A., Electrochemical studies of ganciclovir at glassy carbon electrodes and its direct determination in serum and pharmaceutics by square wave and differential pulse voltammetry. Anal. Chim. Acta 537 (2005), 307–313.
112. Li, C., Wang, G., Wang, S., Lin, X., Determination of ganciclovir by electrochemistry. Huaxue Yanjiu Yu Yingyong 20 (2008), 442–444.
113. Skrzypek, S., Nosal-Wiercińska, A., Ciesielski, W., Electrochemical studies of ganciclovir as the adsorbed catalyst on mercury electrode. Collect. Czech. Chem. Commun. 74 (2009), 1455–1466.
114. Zhou, Y., Zhi, J., Zhang, X., Xu, M., Electrochemical studies of ganciclovir at boron-doped nanocrystalline diamond electrodes. Diamond Relat. Mater. 20 (2011), 18–22.
115. Gholivand, M.B., Karimian, N., Fabrication of a highly selective and sensitive voltammetric ganciclovir sensor based on electropolymerized molecularly imprinted polymer and gold nanoparticles on multiwall carbon nanotubes/glassy carbon electrode. Sens. Actuators B 215 (2015), 471–479.
116. Wang, N.N., Tang, Y.H., Xiong, X.Y., Han, X.N., Yu, C.L., A new flow-injection chemiluminescence method for the determination of acyclovir and gancyclovir. Anal. Lett. 39 (2006), 973–983.
117. Abudukeremu, M., Nannan, W., Yuhai, T., Tu'erhong, M., Determination of acyclovir and gancyclovir using flow-injection chemiluminescence method. J. Xi'an Jiaotong Univ. Med. Sci. 6 (2007), 707–710.
118. Visor, G., Jackson, S.E., Kenley, R.A., Lee, G.C., Reverse-phase HPLC analysis of the antiviral drug, 9-[1,3-dihydroxy-2-popoxy methyl] guanine (DHPG), with amperometric detection. J. Liq. Chromatogr. 8 (1985), 1475–1488.
119. Wiltink, E.H.H., Stekkinger, P., Brakenhoff, J.A.C., Danner, S.A., Determination of 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG) in biological fluids by reversed-phase high pressure liquid chromatography. Pharm. Weekbl. 9 (1987), 261–264.
120. Sommadossi, J.-P., Bevan, R., High-performance liquid chromatographic method for the determination of 9-(1,3-dihydroxy-2-prooxymethyl) guanine in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 414 (1987), 429–433.
121. Hedaya, M.A., Sawchuk, R.J., A sensitive and specific liquid-chromatographic assay for determination of ganciclovir in plasma and urine and its application to pharmacokinetic studies in the rabbits. Pharm. Res. 7 (1990), 1113–1118.
122. Boulieu, R., Bleyzac, N., Ferry, S., Modified high-performance liquid chromatographic method for the determination of ganciclovir in plasma from patients with severe renal impairment. J. Chromatogr. 571 (1991), 331–333.
123. Boulieu, R., Bleyzac, N., Ferry, S., High-performance liquid chromatographic determination of ganciclovir in plasma. J. Chromatogr. 567 (1991), 481–484.
124. Mole, L., Oliva, C., O'Hanley, P., Extended stability of ganciclovir for outpatient parenteral therapy for cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr. 5 (1992), 354–358.
125. Koel, M., Nebinger, P., HPLC determination of serum ganciclovir using ultrafiltration, ultraviolet and fluorescence detection. J. Pharm. Biomed. Anal. 12 (1994), 429–432.
126. Bleyzac, N., Boulieu, R., High-performance liquid chromatographic determination of ganciclovir nucleotides in human myocardial tissue. J. Chromatogr. B Biomed. Appl. 658 (1994), 173–176.
127. McMullin, C.M., Kirk, B., Sunderland, J., White, L.O., Reeves, D.S., Macgowan, A.P., A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum. J. Antimicrob. Chemother. 38 (1996), 739–740.
128. Page, T., Sherwood, C., Connor, J.D., Tarnowski, T., Simple reversed-phase high-performance liquid chromatography quantitation of ganciclovir in human serum and urine. J. Chromatogr. B Biomed. Appl. 675 (1996), 342–346.
129. Cociglio, M., Peyrière, H., Hillaire-Buys, D., Alric, R., Application of a standardized coextractive cleanup procedure to routine high-performance liquid chromatography assays of teicoplanin and ganciclovir in plasma. J. Chromatogr. B Biomed. Sci. Appl. 705 (1998), 79–85.
130. Campanero, M.A., Sadaba, B., García-Quetglas, E., Azanza, J.R., Development and validation of a sensitive method for the determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 706 (1998), 311–317.
131. Wang, M., Huang, M., Yan, Z., Su, H., Determination of ganciclovir in human serum by RP-HPLC. Xi'an Yike Daxue Xuebao 20 (1999), 571–572.
132. Chu, F., Kiangm, C.H., Sung, M.L., Huang, B., Reeve, R.L., Tarnowski, T., A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. J. Pharm. Biomed. Anal. 21 (1999), 657–667.
133. Merodio, M., Campanero, M.A., Mirshahi, T., Mirshahi, M., Irache, J.M., Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography. J. Chromatogr. A 870 (2000), 159–167.
134. Shibata, N., Kitamura, A., Yoshikawa, Y., Inoue, T., Bamba, T., Takada, K., Simultaneous determination of aciclovir and ganciclovir in plasma by HPLC and pharmacokinetic interactions. Pharm. Pharmacol. Commun. 6 (2000), 501–506.
135. Tsuchie, M., Hara, S., Kimura, M., Mujii, F., Ono, N., Kai, M., Determination of anti-virus drug, ganciclovir, in human serum by HPLC with precolumn fluorescence derivatization using phenylglyoxal. Anal. Sci. 17 (2001), 811–814.
136. Kishino, S., Takekuma, Y., Sugawara, M., Shimamura, T., Furukawa, H., Todo, S., Miyazaki, K., Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 780 (2002), 289–294.
137. Teshima, D., Otsubo, K., Yoshida, T., Itoh, Y., Oishi, R., A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 17 (2003), 500–503.
138. Li, Z., Determination of ganciclovir for injection by HPLC. Zhongguo Yiyao Gongye Zazhi 34 (2003), 30–31.
139. Tang, X., Chen, L., Wu, W., Ye, C., Determination of ganciclovir eye drops by HPLC. Zhongguo Yiyuan Yaoxue Zazhi 23 (2003), 740–741.
140. Liang, C.-R., Xu, Z.-Z., Dong, P., Determination of ganciclovir and its related substances by HPLC. J. China Pharm. Univ. 35 (2004), 135–137.
141. Gao, X.-K., Amount determination of ganciclovir injection and its related substances by RP-HPLC. Yaoxue Jinzhan 29 (2005), 520–522.
142. Wu, W., He, F., Determination of ganciclovir concentration in dog serum by RP-HPLC. Di-San Junyi Daxue Xuebao 28 (2006), 1407–1408.
143. Liang, G.-L., HPLC determination of ganciclovir and ribavirin in eye drops. Chin. J. Pharm. Anal. 26 (2006), 1308–1310.
144. Perrottet, N., Beguin, A., Meylan, P., Pascual, M., Manuel, O., Buclin, T., Biollaz, J., Decosterd, L.A., Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852 (2007), 420–429.
145. Åsberg, A., Hansen, C.N., Reubsaet, L., Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs. J. Pharm. Biomed. Anal. 43 (2007), 1039–1044.
146. Shen, Y., Tu, J.-S., Lu, Y., Lin, L., Determination of ganciclovir in rabbit aqueous humor and pharmacokinetics of its eyedrops. Chin. J. Clin.Pharm. 16 (2007), 199–203.
147. Li, L., Wang, W., Yang, X., Yang, C., Determination of ganciclovir content in its glucose injection by HPLC. Zhongguo Yiyuan Yaoxue Zazhi 27 (2007), 988–989.
148. Zhang, R., Chen, L., Zhang, L., Determination of ganciclovir in liver perfusate with reversed phase HPLC. Yiyao Daobao 27 (2008), 1043–1044.
149. Dao, Y.J., Jiao, Z., Zhong, M.K., Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867 (2008), 270–276.
150. Weller, D.R., Balfour, H.H., Vezina, H.E., Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography. Biomed. Chromatogr. 23 (2009), 822–827.
151. Guo, X., Yang, K., Li, S., Content determination of ganciclovir and glucose injection by HPLC. Zhongguo Yaoy 18 (2009), 30–31.
152. Yoshida, T., Takahashi, R., Imai, K., Uchida, H., Arai, Y., Ohishi, T., A simple, sensitive determination of ganciclovir in infant plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. Sci. 48 (2010), 208–211.
153. Sarsambi, P.S., Sonawane, A., Faheem, A., Development and validation of RP-HPLC method for the determination of ganciclovir in bulk drug and its formulations. Int. J. Pharm. Bio Sci., V1(2), 2010 7 pages.
154. Gowrisankar, D., Sarsambi, P.S., Kalyan, K., Reverse phase-high performance liquid chromatographic method for the analysis of ganciclovir in bulk drug and its pharmaceutical formulations. Pharma Sci. Monit., 2(Suppl. 1), 2011 S-168-S-175.
155. Padullés, A., Colom, H., Armendariz, Y., Cerezo, G., Caldes, A., Pou, L., Torras, J., Grinyó J.M., Lloberas, N., Determination of ganciclovir in human plasma by ultra performance liquid chromatography-UV detection. Clin. Biochem. 45 (2012), 309–314.
156. Ramesh, P.J., Basavaiah, K., Vinay, K.B., Xavier, C.M., Development and validation of RP-HPLC method for the determination of ganciclovir in bulk drug and in formulations. ISRN Chromatogr., 2012, 2012, 8 pages 1–8.
157. Xu, K., Lanuti, M., Lambright, E.S., Force, S.D., Albelda, S.M., Blair, I.A., A rapid and sensitive method for the quantification of ganciclovir in plasma using liquid chromatography/selected reaction monitoring/mass spectrometry. Biomed. Chromatogr. 14 (2000), 93–98.
158. Xu, H.R., Li, X.N., Chen, W.L., Liu, G.Y., Chu, N.N., Yu, C., A sensitive assay for simultaneous determination of plasma concentrations of valganciclovir and its active metabolite ganciclovir by LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848 (2007), 329–334.
159. Li, C.-P., Mao, M., Zheng, L.-J., Shan, W.-G., Analysis of ganciclovir and its related substances using high performance liquid chromatography and liquid chromatography-mass spectrometry methods. Acad. J. Xi'an Jiaotong Univ. 22 (2010), 218–222.
160. Heinig, K., Wirz, K.T., Gajate-Perez, A., Belli, S., Determination of ganciclovir and its prodrug valganciclovir by hydrophilic interaction liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879 (2011), 436–442.
161. Singh, O., Saxena, O.S., Mishra, S., Khuroo, A., Monif, T., Determination of valganciclovir and ganciclovir in human plasma by liquid chromatography tandem mass spectrometric detection. Clin. Biochem. 44 (2011), 907–915.
162. Rigo-Bonnin, R., Padullés, A., Corral-Comesaña, S., Cerezo, G., Grinyó J.M., Colom, H., Alía-Ramos, P., Lloberas, N., Measurement of ganciclovir concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Clin. Chim. Acta 427 (2014), 58–64.
163. Billat, P.A., FL Sauvage, N., Picard, N., Tafzi, S., Alain, M., Essig, P.M., Saint-Marcoux, F., Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms. Anal. Bioanal. Chem. 40 (2015), 3449–3456.
164. Gunda, S., Earla, R., Cholkar, K., Mitra, A.K., Pharmacokinetic studies and LC-MS/MS method development of ganciclovir and dipeptide monoester prodrugs in Sprague Dawley rats. Eur. J. Drug Metab. Pharmacokinet. 40 (2015), 325–334.
165. Song, F.Y., Liang, H.M., Wu, F.H., Determination of ganciclovir injection by high-performance capillary electrophoresis-conductivity detection. Guangdong Yaoxueyuan Xuebao 19 (2003), 122–123.
166. Saleh, S., Hempel, G., Quantification of ganciclovir in human plasma using capillary electrophoresis. Electrophoresis 27 (2006), 2439–2443.
167. Nerenberg, C., McClung, S., Martin, J., Fass, M., La Fargue, J.A., Kushinsky, S., A radioimmunoassay procedure for the determination of the antiviral nucleoside DHPG (9-[(l,3-dihydroxy-2-propoxy)-methyl]guanine) in plasma or serum. Pharm. Res. 3 (1986), 112–115.
168. Tadepalli, S.M., Quinn, R.P., Averett, D.R., A competitive enzyme-linked immunosorbent assay to quantitate acyclovir and BW B759U in human plasma and urine. Antimicrob. Agents Chemother. 29 (1986), 93–98.
169. Henry, K., Cantrill, H., Fletcher, C., Chinnock, B.J., Balfour, H.H. Jr., Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am. J. Ophthalmol. 103 (1987), 17–23.
170. Fletcher, C., Sawchuk, R., Chinnock, B., de Miranda, P., Balfour, H.H. Jr., Human pharmacokinetics of the antiviral drug DHPG. Clin. Pharmacol. Ther. 40 (1986), 281–286.
171. Jacobson, M.A., de Miranda, P., Cederberg, D.M., Burnette, T., Cobb, E., Brodie, H.R., Mills, J., Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob. Agents Chemother. 31 (1987), 1251–1254.
172. Sommadossi, J.-P., Bevan, R., Ling, T., Lee, F., Mastre, B., Chaplin, M.D., Nerenberg, C., Koretz, S., Buhles, W. Jr., Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Clin. Infect. Dis. 10:Suppl. 3 (1988), S507–S514.
173. Sommadossi, J.-P., Bevan, R., Ling, T., Lee, F., Mastre, B., Chaplin, M.D., Nerenberg, C., Koretz, S., Buhles, W. Jr., Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev. Infect. Dis. 10:Suppl. 3 (1988), S507–S514.
174. Swan, S.K., Munar, M.Y., Wigger, M.A., Bennett, W.M., Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis. Am. J. Kidney Dis. 17 (1991), 69–72.
175. Jacqz-Aigrain, E., Macher, M.A., Sauvageon-Marthem, H., Brun, P., Loirat, C., Pharmacokinetics of ganciclovir in renal transplant children. Pediatr. Nephrol. 6 (1992), 194–196.
176. Trang, J.M., Kidd, L., Gruber, W., Storch, G., Demmler, G., Jacobs, R., Dankner, W., Starr, S., Pass, R., Stagno, S., et al. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Clin. Pharmacol. Ther. 53 (1993), 15–21.
177. Combarnous, F., Fouque, D., Bernard, N., Boulieu, R., Chossegros, P., Laville, M., Zech, P., Pharmacokinetics of ganciclovir in a patient undergoing chronic haemodialysis. Eur. J. Clin. Pharmacol. 46 (1994), 379–381.
178. Spector, S.A., Busch, D.F., Follansbee, S., Squires, K., Lalezari, J.P., Jacobson, M.A., Connor, J.D., Jung, D., Shadman, A., Mastre, B., Buhles, W., Drew, W.L., Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J. Infect. Dis. 171 (1995), 1431–1437.
179. Zhou, X.J., Gruber, W., Demmler, G., Jacobs, R., Reuman, P., Adler, S., Shelton, M., Pass, R., Britt, B., Trang, J.M., Whitley, R.J., Sommadossi, J.-P., Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group. Antimicrob. Agents Chemother. 40 (1996), 2202–2205.
180. Snell, G.I., Kotsimbos, T.C., Levvey, B.J., Skiba, M., Rutherford, D.M., Kong, D.C.M., Williams, T.J., Krum, H., Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. J. Antimicrob. Chemother. 45 (1999), 511–551.
181. Serabe, B.M., Murry, D.J., Dauser, R., Nuchtern, J., Durfee, J., McGuffey, L., Berg, S., Blaney, S.M., Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer Chemother. Pharmacol. 43 (1999), 415–418.
182. Brown, F., Banken, L., Saywell, K., Arum, I., Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin. Pharmacokinet. 37 (1999), 167–176.
183. Norris, D.A., Leesman, G.D., Sinko, P.J., Grass, G.M., Development of predictive pharmacokinetic simulation models for drug discovery. J. Control. Release 65 (2000), 55–62.
184. Frenkel, L.M., Capparelli, E.V., Dankner, W.M., Xu, J., Smith, I.L., Ballow, A., Culnane, M., Read, J.S., Thompson, M., Mohan, K.M., Shaver, A., Robinson, C.A., Stempien, M.J., Burchett, S.K., Melvin, A.J., Borkowsky, W., Petru, A., Kovacs, A., Yogev, R., Goldsmith, J., McFarland, E.J., Spector, S.A., Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. J. Infect. Dis. 182 (2000), 1616–1624.
185. Pescovitz, M.D., Rabkin, J., Merion, R.M., Paya, C.V., Pirsch, J., Freeman, R.B., O'Grady, J., Robinson, C., To, Z., Wren, K., Banken, L., Buhles, W., Brown, F., Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44 (2000), 2811–2815.
186. López-Cortés, L.F., Pastor-Ramos, M.T., Ruiz-Valderas, R., Cordero, E., Uceda-Montañés, A., Claro-Cala, C.M., Lucero-Muñoz, M.J., Intravitreal pharmacokinetics and retinal concentrations of ganciclovir and foscarnet after intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 42 (2001), 1024–1028.
187. Czockm, D., Scholle, C., Rasche, F.M., Schaarschmidt, D., Keller, F., Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin. Pharmacol. Ther. 72 (2002), 142–150.
188. Zhang, D., Lapeyraque, A.L., Popon, M., Loirat, C., Jacqz-Aigrain, E., Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr. Nephrol. 18 (2003), 943–948.
189. Zhang, J.J., Gao, C.F., Wang, L.Y., Ocular pharmacokinetics and bioavailability of 0.2% ganciclovir in-situ gelling eye drops. Zhonghua Yan Ke Za Zhi 42 (2006), 637–641.
190. Asano-Mori, Y., Kanda, Y., Oshima, K., Watanabe, T., Shoda, E., Motokura, T., Kurokawa, M., Chiba, S., Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J. Antimicrob. Chemother. 57 (2006), 1004–1007.
191. Wiltshire, H., Hirankarn, S., Farrell, C., Paya, C., Pescovitz, M.D., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin. Pharmacokinet. 44 (2005), 495–507.
192. Winston, D.J., Ratanatharathorn, V., Baden, L., Emmanouilides, C., Gabriel, D., Li, S., Lange, W.R., Pharmacokinetics of ganciclovir following oral valganciclovir versus intravenous ganciclovir in allogeneic hematopoietic stem-cell transplant patients with stable graft-versus-host disease of the gastrointestinal tract. Blood, 104, 2004, 2223.
193. Winston, D.J., Baden, L.R., Gabriel, D.A., Emmanouilides, C., Shaw, L.M., Lange, W.R., Ratanatharathorn, V., Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol. Blood Marrow Transplant. 12 (2006), 635–640.
194. Acosta, E.P., Brundage, R.C., King, J.R., Sánchez, P.J., Sood, S., Agrawal, V., Homans, J., Jacobs, R.F., Lang, D., Romero, J.R., Griffin, J., Cloud, G., Whitley, R., Kimberlin, D.W., Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin. Pharmacol. Ther. 81 (2007), 867–872.
195. Ashton, P., Brown, J.D., Pearson, P.A., Blandford, D.L., Smith, T.J., Anand, R., Nightingale, S.D., Sanborn, G.E., Intravitreal ganciclovir pharmacokinetics in rabbits and man. J. Ocul. Pharmacol. Ther. 8 (2009), 343–347.
196. Shen, Y., Tu, J., Preparation and ocular pharmacokinetics of ganciclovir liposomes. Am. Assoc. Pharm. Sci. J. 9 (2007), E371–E377.
197. Zhao, W., Baudouin, V., Zhang, D., Deschênes, G., Le Guellec, C., Jacqz-Aigrain, E., Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin. Pharmacokinet. 48 (2009), 321–328.
198. Perrottet, N., Csajka, C., Pascual, M., Manuel, O., Lamoth, F., Meylan, P., Aubert, J.D., Venetz, J.P., Soccal, P., Decosterd, L.A., Biollaz, J., Buclin, T., Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob. Agents Chemother. 53 (2009), 3017–3023.
199. Caldés, A., Colom, H., Armendariz, Y., Garrido, M.J., Troconiz, I.F., Gil-Vernet, S., Lloberas, N., Pou, L., Peraire, C., Grinyó J.M., Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob. Agents Chemother. 53 (2009), 4816–4824.
200. o23. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days, vol. 90, 2010, Vancouver, Canada, 1414–1419.
201. Carmichael, R.J., Whitfield, C., Maxwell, L.K., Pharmacokinetics of ganciclovir and valganciclovir in the adult horse. J. Vet. Pharmacol. Ther. 36 (2013), 441–449.
202. McGloughlin, S., Roberts, J.A., O'Donoghue, S., Martin, J., Briscoe, S., Lipman, J., Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. Int. J. Antimicrob. Agents 37 (2011), 90–92.
203. Kiser, T.H., Fish, D.N., Zamora, M.R., Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. J. Heart Lung Transplant. 31 (2012), 159–166.
204. Horvatits, T., Kitzberger, R., Drolzm, A., Zauner, C., Jäger, W., Böhmdorfer, M., Kraff, S., Fritsch, A., Thalhammer, F., Fuhrmann, V., Schenk, P., Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. Antimicrob. Agents Chemother. 58 (2014), 94–101.
205. Vezina, H.E., Brundage, R.C., Balfour, H.H. Jr., Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. Br. J. Clin. Pharmacol. 78 (2014), 343–352.
206. Gynther, M., Kääriäinen, T.M., Hakkarainen, J.J., Jalkanen, A.J., Petsalo, A., Lehtonen, M., Peura, L., Kurkipuro, J., Samaranayake, H., Ylä-Herttuala, S., Rautio, J., Forsberg, M.M., Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma. Drug Metab. Dispos. 43 (2015), 140–146.
207. Stockmann, C., Roberts, J.K., Knackstedt, E.D., Spigarelli, M.G., Sherwin, C.M.T., Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert Opin. Drug Metab. Toxicol. 11 (2015), 205–219.
208. Lukacova, V., Goelzer, P., Reddy, M., Greig, G., Reigner, B., Parrott, N., A physiologically-based pharmacokinetic model for ganciclovir and its prodrug valganciclovir in adults and children. Am. Assoc. Pharm. Sci. J. 18 (2016), 1453–1463.
209. Boujemla, I., Fakhoury, M., Nassar, M., Adle-Biassette, H., Hurteaud, M.F., Jacqz-Aigrain, E., Gressens, P., Teissier, N., Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 132 (2016), 111–115.
210. Oklebrrye, K.M., Warren, R.P., Smee, D.F., Metabolism of ganciclovir and cidofovir in cells infected with drug-resistant and wild-type strains of murine cytomegalovirus. Antiviral Res. 35 (1997), 83–90.
211. De Bolle, L., Michel, D., Manichanh, C., Agut, H., De Clercq, E., Naesens, L., Role of the human herpesvirus 6 u69-encoded kinase in the phosphorylation of ganciclovir. Mol. Pharmacol. 62 (2002), 714–721.
212. Ansari, A., Emery, V.C., The U69 gene of human herpesvirus 6 encodes a protein kinase which can confer ganciclovir sensitivity to baculoviruses. J. Virol. 73 (1999), 3284–3291.
213. Gentry, B.G., Drach, J.C., Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells. Antimicrob. Agents Chemother. 58 (2014), 2329–2333.
214. Zhou, S., Breitenbach, J.M., Borysko, K.Z., Drach, J.C., Kern, E.R., Gullen, E., Cheng, Y.-C., Zemlicka, J., Synthesis and antiviral activity of (Z)- and (E)-2,2[bis(hydroxymethyl)cyclopropylidene]methyl-purines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleoside. J. Med. Chem. 47 (2004), 566–575.
215. Billat, P.-A., Woillard, J.-B., Sauvage, F.-L., Saint-Marcoux, F., Ganciclovir and its metabolites optimized pharmacokinetic modelling for exposure-effect in adult renal transplant recipients. J. Antimicrob. Chemother. 29 (2015), 10–11.
216. Ray, A.S., Olson, L., Fridland, A., Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 60 (2016), 1089–1095.
217. Brewster, M.E., Raghavan, K., Pop, E., Bodor, N., Enhanced delivery of ganciclovir to the brain through the use of redox targeting. Antimicrob. Agents Chemother. 38 (1994), 817–823.
218. Anderson, R.D., Griffy, K.G., Jung, D., Dorr, A., Hulse, J.D., Smith, R.B., Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus-and cytomegalovirus-seropositive patients. Clin. Ther. 17 (1995), 425–432.
219. Drew, W.L., Ives, D., Lalezari, J.P., Crumpacker, C., Follansbee, S.E., Spector, S.A., Benson, C.A., Friedberg, D.N., Hubbard, L., Stempien, M.J., et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N. Engl. J. Med. 333 (1995), 615–620.
220. Lavelle, J., Follansbee, S., Trapnell, C.B., Buhles, W.C., Griffy, K.G., Jung, D., Dorr, A., Connor, J., Effect of food on the relative bioavailability of oral ganciclovir. J. Clin. Pharmacol. 36 (1996), 238–241.
221. Jung, D., Griffy, K., Wong, R., Colburn, W., Hulse, J., Absolute bioavailability and dose proportionality of oral ganciclovir after ascending multiple doses in human immunodeficiency virus (HIV)-positive patients. J. Clin. Pharmacol. 38 (1998), 1122–1128.
222. Jung, D., AbdelHameed, M.H., Hunter, J., Teitelbaum, P., Dorr, A., Griffy, K., The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV- and CMV-seropositive patients. Br. J. Clin. Pharmacol. 47 (1999), 255–259.
223. Tojo, K., Nakagawa, K., Morita, Y., Ohtori, A., A pharmacokinetic model of intravitreal delivery of ganciclovir. Eur. J. Pharm. Biopharm. 47 (1999), 99–104.
224. Mouly, S., Aymard, G., Tillement, J.-P., Caulin, C., Bergmann, J.-F., Urien, S., Increased oral ganciclovir bioavailability in HIV-infected patients with chronic diarrhoea and wasting syndrome—a population pharmacokinetic study. Br. J. Clin.Pharmacol. 51 (2001), 557–565.
225. Hiatt, J.A., Warren, K.A., Kasper, J.S., Saghir, S.A., Szabo, I., Rozman, K.K., Bioavailability of ganciclovir from a sustained-release ganciclovir intraocular implant in silicone oil: an in vitro study. Invest. Ophthalmol. Vis. Sci., 44, 2003, 4619.
226. Shah, P., Jogani, V., Mishra, P., Mishra, A.K., Bagchi, T., Misra, A., Modulation of ganciclovir intestinal absorption in presence of absorption enhancers. J. Pharm. Sci. 96 (2007), 2710–2722.
227. Akhter, S., Kushwaha, S., Warsi, M.H., Anwar, M., Ahmad, M.Z., Ahmad, I., Talegaonkar, S., Khan, Z.I., Khar, R.K., Ahmad, F.J., Development and evaluation of nanosized niosomal dispersion for oral delivery of ganciclovir. Drug Dev. Ind. Pharm. 38 (2012), 84–92.
228. Kapanigowda, U.G., Nagaraja, S.H., Ramaiah, B., Boggarapu, P.R., Improved intraocular bioavailability of ganciclovir by mucoadhesive polymer based ocular microspheres: development and simulation process in Wistar rats. Daru, 24, 2015, 49.
229. Matthews, T., Boehme, R., Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10 (1988), S490–S494.
230. Fletcher, C.V., Balfour, H.H. Jr., Evaluation of ganciclovir for cytomegalovirus disease. DICP 23 (1989), 5–12.
231. Gerna, G., Zipeto, D., Parea, M., Revello, M.G., Silini, E., Percivalle, E., Zavattoni, M., Grossi, P., Milanesi, G., Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J. Infect. Dis. 164 (1991), 488–498.
232. Goodrich, J.M., Mori, M., Gleaves, C.A., Du Mond, C., Cays, M., Ebeling, D.F., Buhles, W.C., DeArmond, B., Meyers, J.D., Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N. Engl. J. Med. 325 (1991), 1601–1607.
233. Gerna, G., Baldanti, F., Zavattoni, M., Sarasini, A., Percivalle, E., Revello, M.G., Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antiviral Res. 19 (1992), 333–345.
234. Sullivan, S.D., Mozaffari, E., Johnson, E.S., Wolitz, R., Follansbee, S.E., An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients. Clin. Ther. 18 (1996), 546–558.
235. Marenzi, R., Cinque, P., Ceresa, D., Racca, S., Lillo, F., Lazzarin, A., Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients. Scand. J. Infect. Dis. 28 (1996), 347–351.
236. Hardens, M., Ganciclovir evaluation in AIDS patients with cytomegalovirus retinitis: a European study of treatment patterns and resource utilization. AIDS 4 (1996), S25–S30.
237. Whitley, R.J., Cloud, G., Gruber, W., Storch, G.A., Demmler, G.J., Jacobs, R.F., Dankner, W., Spector, S.A., Starr, S., Pass, R.F., Stagno, S., Britt, W.J., Alford, C. Jr., Soong, S., Zhou, X.J., Sherrill, L., FitzGerald, J.M., Sommadossi, J.-P., Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J. Infect. Dis. 175 (1997), 1080–1086.
238. Dos Santos Mde, F., Dos Santos, O.F., Boim, M.A., Razvickas, C.V., de Moura, L.A., Ajzen, H., Schor, N., Nephrotoxicity of acyclovir and ganciclovir in rats: evaluation of glomerular hemodynamics. J. Am. Soc. Nephrol. 8 (1997), 361–367.
239. Pavić I., Hartmann, A., Zimmermann, A., Michel, D., Hampl, W., Schleyer, I., Mertens, T., Flow cytometric analysis of herpes simplex virus type 1 susceptibility to acyclovir, ganciclovir, and foscarnet. Antimicrob. Agents Chemother. 41 (1997), 2686–2692.
240. Gambhir, S.S., Barrio, J.R., Wu, L., Iyer, M., Namavari, M., Satyamurthy, N., Bauer, E., Parrish, C., MacLaren, D.C., Borghei, A.R., Green, L.A., Sharfstein, S., Berk, A.J., Cherry, S.R., Phelps, M.E., Herschman, H.R., Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J. Nucl. Med. 39 (1998), 2003–2011.
241. McSharry, J.M., Lurain, N.S., Drusano, G.L., Landay, A., Manischewitz, J., Nokta, M., O'Gorman, M., Shapiro, H.M., Weinberg, A., Reichelderfer, P., Crumpacker, C., Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. J. Clin. Microbiol. 36 (1998), 958–964.
242. Filler, G., Lampe, D., von Bredow, M.A., Lappenberg-Pelzer, M., Rocher, S., Strehlau, J., Ehrich, J.H., Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Pediatr. Nephrol. 12 (1998), 6–9.
243. Duan, J., Paris, W., Kibler, P., Bousquet, C., Liuzzi, M., Cordingley, M.G., Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 39 (1998), 189–197.
244. Aitken, C., Hawrami, K., Miller, C., Barrett, M.W., Yaqoob, M., Breuer, J., Simultaneous treatment of cytomegalovirus and varicella zoster infections in a renal transplant recipient with ganciclovir: use of viral load to monitor response to treatment. J. Med. Virol. 59 (1999), 412–414.
245. Martin, D.F., Kuppermann, B.D., Wolitz, R.A., Palestine, A.G., Li, H., Robinson, C.A., Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N. Engl. J. Med. 340 (1999), 1063–1070.
246. Muccioli, C., Belfort, R. Jr., Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. Braz. J. Med. Biol. Res. 33 (2000), 779–789.
247. Piketty, C., Bardin, C., Gilquin, J., Gairard, A., Kazatchkine, M.D., Chast, F., Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin. Microbiol. Infect. 6 (2000), 117–120.
248. Amjad, M., Gillespie, M.A., Carlson, R.M., Karim, M.R., Flow cytometric evaluation of antiviral agents against human herpesvirus 6. Microbiol. Immunol. 45 (2001), 233–240.
249. Singh, N., Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin. Infect. Dis. 32 (2001), 742–751.
250. Fischler, B., Casswall, T.H., Malmborg, P., Nemeth, A., Ganciclovir treatment in infants with cytomegalovirus infection and cholestasis. J. Pediatr. Gastroenterol. Nutr. 34 (2002), 154–157.
251. Nicolazzi, C., Venard, V., Le Faou, A., Finance, C., In vitro antiviral efficacy of the ganciclovir complexed with beta-cyclodextrin on human cytomegalovirus clinical strains. Antiviral Res. 54 (2002), 121–127.
252. Baldanti, F., Michel, D., Simoncini, L., Heuschmid, M., Zimmermann, A., Minisini, R., Schaarschmidt, P., Schmid, T., Gerna, G., Mertens, T., Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res. 54 (2002), 59–67.
253. Limaye, A.P., Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35 (2002), 866–872.
254. Reusser, P., Einsele, H., Lee, J., Volin, L., Rovira, M., Engelhard, D., Finke, J., Cordonnier, C., Link, H., Ljungman, P., Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99 (2002), 1159–1164.
255. Long, M.C., Bidanset, D.J., Williams, S.L., Kushner, N.L., Kern, E.R., Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry. Antiviral Res. 58 (2003), 149–157.
256. Kimberlin, D.W., Lin, C.Y., Sánchez, P.J., Demmler, G.J., Dankner, W., Shelton, M., Jacobs, R.F., Vaudry, W., Pass, R.F., Kiell, J.M., Soong, S.J., Whitley, R.J., Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J. Pediatr. 143 (2003), 16–25.
257. Paya, C., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., Pescovitz, M.D., Valganciclovir Solid Organ Transplant Study Group, Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 4 (2004), 611–620.
258. Scott, J.C., Partovi, N., Ensom, M.H.H., Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring?. Ther. Drug Monit. 26 (2004), 68–77.
259. Czock, D., Rasche, F.M., New AUC-based method to estimate drug fraction removed by hemodialysis. Kidney Blood Press. Res. 27 (2004), 172–176.
260. Biron, K.K., Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71 (2006), 154–163.
261. Einsele, H., Reusser, P., Bornhäuser, M., Kalhs, P., Ehninger, G., Hebart, H., Chalandon, Y., Kröger, N., Hertenstein, B., Rohde, F., Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107 (2006), 3002–3008.
262. Smets, K., De Coen, K., Dhooge, I., Standaert, L., Laroche, S., Mahieu, L., Logghe, N., Cossey, V., Boudewyns, A., Selecting neonates with congenital cytomegalovirus infection for ganciclovir therapy. Eur. J. Pediatr. 165 (2006), 885–890.
263. Ljungman, P., Dahl, H., Xu, Y.H., Larsson, K., Brytting, M., Linde, A., Effectiveness of ganciclovir against human herpesvirus-6 excreted in saliva in stem cell transplant recipients. Bone Marrow Transplant. 39 (2007), 497–499.
264. Ozkan, T.B., Mistik, R., Dikici, B., Nazlioglu, H.O., Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis. BMC Gastroenterol., 7, 2007, 9 (1–5).
265. Stewart, M.W., Optimal management of cytomegalovirus retinitis in patients with AIDS. Clin. Ophthalmol. 4 (2010), 285–299.
266. Luck, S., Lovering, A., Griffiths, P., Sharland, M., Ganciclovir treatment in children: evidence of subtherapeutic levels. Int. J. Antimicrob. Agents 37 (2011), 445–448.
267. Yeh, S., Fahle, G., Forooghian, F., Faia, L.J., Weichel, E.D., Stout, J.T., Flaxel, C.J., Lauer, A.K., Sen, H.N., Nussenblatt, R.B., Polymerase chain reaction-based ganciclovir-resistance testing of ocular fluids for cytomegalovirus retinitis. Arch. Ophthalmol. 130 (2012), 113–115.
268. Janoly-Dumenil, A., Rouvet, I., Bleyzac, N., Morfin, F., Zabot, M.-T., Tod, M., A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection. Antimicrob. Agents Chemother. 56 (2012), 3732–3738.
269. Bedino, G., Esposito, P., Bosio, F., Corradetti, V., Valsania, T., Rocca, C., Pattonieri, E.F., Gregorini, M., Rampino, T., Canton, A.D., The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. Int. Urol. Nephrol. 45 (2013), 1809–1813.
270. Ruiz-Carrascoso, G., Romero-Gómez, M.P., Plaza, D., Mingorance, J., Rapid detection and quantitation of ganciclovir resistance in cytomegalovirus quasispecies. J. Med. Virol. 85 (2013), 1250–1257.
271. Chen, H., Beardsley, G.P., Coen, D.M., Mechanism of ganciclovir-induced chain termination revealed by resistant viral polymerase mutants with reduced exonuclease activity. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 17462–17467.
272. Huang, J., Kadonosono, K., Uchio, E., Antiadenoviral effects of ganciclovir in types inducing keratoconjunctivitis by quantitative polymerase chain reaction methods. Clin. Ophthalmol. 8:2014 (2014), 315–320.
273. Ding, Z., Mathur, V., Ho, P.P., James, M.L., Lucin, K.M., Hoehne, A., Alabsi, H., Gambhir, S.S., Steinman, L., Luo, J., Wyss-Coray, T., Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. J. Exp. Med., 211, 2014, 189.
274. + T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. Antimicrob. Agents Chemother. 58 (2014), 5602–5605.
275. Javad Hosseini, S.M., Nemati, E., Behzadian, F., Einollahi, B., Rahimi Petrudy, A., Sohraby, M., Taghipour, M., Motalebi, M., Evaluation of ganciclovir resistance in cytomegalovirus infection of renal transplant recipients in Tehran. Transplant. Proc. 47 (2015), 1140–1142.
276. Natale, F., Bizzarri, B., Cardi, V., De Curtis, M., Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection Neonatology and Fetal Medicine. Ital. J. Pediatr., 41, 2015, 26 (1–3).
277. Menghi, V., Comai, G., Baraldi, O., D'Arcangelo, G.L., Lazzarotto, T., La Manna, G., Ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient successfully treated with foscarnet and everolimus. Case Rep. Nephrol., 2016, 2016, 2736805 4 pages.
278. Sunada, M., Kinoshita, D., Furukawa, N., Kihara, M., Nishimura, A., Moriuchi, M., Moriuchi, H., Therapeutic drug monitoring of ganciclovir for postnatal cytomegalovirus infection in an extremely low birth weight infant: a case report. BMC Pediatr., 16, 2016, 141 (1–4).
279. Mozaffar, M., Shahidi, S., Badri, S., Ganciclovir use evaluation in kidney transplantation departments. J. Res. Pharm. Pract. 5 (2016), 212–214.
280. Sohrabi, M., Behzadian, F., Hosseini, S.M., Lashini, H., Molecular analysis of ganciclovir-resistant cytomegalovirus in renal transplant recipients with high viral load. Arch. Iran. Med. 19 (2016), 700–703.
281. Visor, G.C., Lin, L.H., Jackson, S.E., Winterle, J.S., Lee, G., Kenley, R.A., Stability of ganciclovir sodium (DHPG sodium) in 5% dextrose or 0.9% sodium chloride injections. Am. J. Hosp. Pharm. 43 (1986), 2810–2812.
282. Silvestri, A.P., Mitrano, F.P., Baptista, R.J., Williams, D.A., Stability and compatibility of ganciclovir sodium in 5% dextrose injection over 35 days. Am. J. Hosp. Pharm. 48 (1991), 2641–2643.
283. Phaypradith, S., Vigneron, J., Perrin, A., Durney-Archeray, M.J., Hoffman, M.A., Hoffman, M., Stability of dilute solutions of ganciclovir sodium (Cymevan) in polypropylene syringes and PVC perfusion bags. J. Pharm. Belg. 47 (1992), 494–498.
284. Parasrampuria, J., Li, L.C., Stelmach, A.H., Sykes, T.R., Gordon, G.A., Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days. Am. J. Hosp. Pharm. 49 (1992), 116–118.
285. Boulieu, R., Bleyzac, N., Stability of ganciclovir in blood samples. J. Pharm. Biomed. Anal. 12 (1994), 1205–1207.
286. Mulye, N.V., Turco, S.J., Speaker, T.J., Stability of ganciclovir sodium in an infusion-pump syringe. Am. J. Hosp. Pharm. 51 (1994), 1348–1349.
287. Johnson, C.E., Jacobson, P.A., Chan, E., Stability of ganciclovir sodium and amino acids in parenteral nutrient solutions. Am. J. Hosp. Pharm. 51 (1994), 503–508.
288. Anaizi, N.H., Swenson, C.F., Dentinger, P.J., Stability of ganciclovir in extemporaneously compounded oral liquids. Am. J. Health Syst. Pharm. 56 (1999), 1738–1741.
289. Tomasello, C., Giacomotti, M.M., D'Avolio, A., Simiele, M., Leggieri, A., Perri, G.D., TCH-042 stability study of ganciclovir in 0.9% sodium chloride in different types of containers: optimization of resources. Eur. J. Hosp. Pharm., 20, 2013, A83.
290. Srisangchun, J., Noppawinyoowong, C., Chemical stability and sterility of frozen ganciclovir injections. Srinagarind Med. J. 23 (2008), 2–6 http://imsear.hellis.org/handle/123456789/134105.
291. Fan-Havard, P., Nahata, M.C., Brady, M.T., Ganciclovir—a review of pharmacology, therapeutic efficacy and potential use for treatment of congenital cytomegalovirus infections. J. Clin. Pharm. Ther. 14 (1989), 329–340.
292. Riley, C.M., Ault, J.M. Jr., Klutman, N.E., Chromatographic methods for the bioanalysis of antiviral agents. J. Chromatogr. B Biomed. Sci. Appl. 531 (1990), 295–368.
293. Tseng, A., Foisy, M., The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: pharmacological review and update on new developments. Can. J. Infect. Dis. 7 (1996), 183–194.
294. Kanj, S.S., Sharara, A.I., Clavien, P.A., Hamilton, J.D., Cytomegalovirus infection following liver transplantation: review of the literature. Clin. Infect. Dis. 22 (1996), 537–549.
295. Perry, C.M., Davis, R., Ganciclovir. A pharmacoeconomic review of its use as intravenous or oral maintenance therapy in the management of cytomegalovirus retinitis in patients with AIDS. Pharmacoeconomics 12 (1997), 209–228.
296. Gutiéerrez, C.A., Chaparro, C., Krajden, M., Winton, T., Kesten, S., Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 113 (1998), 924–932.
297. Gao, H., Mitra, A.K., Synthesis of acyclovir, ganciclovir and their prodrugs: a review. Synthesis 3 (2000), 329–351.
298. Vajpayee, M., Malhotra, N., Antiviral drugs against herpes infections. Indian J. Pharm. 32 (2000), 330–338.
299. Chang, M., Dunn, J.P., Ganciclovir implant in the treatment of cytomegalovirus retinitis. Expert Rev. Med. Devices 2 (2005), 421–427.
300. Rafailidis, P.I., Mourtzoukou, E.G., Varbobitis, I.C., Falagas, M.E., Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol. J., 5, 2008, 47.
301. Avery, R.K., Update in management of ganciclovir-resistant cytomegalovirus infection. Curr. Opin. Infect. Dis. 21 (2008), 433–437.
302. Bosch, M.E., Sánchez, A.J.R., Rojas, F.S., Bosch-Ojeda, C., Ganciclovir: a review of its analytical determination. Asian J. Pharm. Sci. 4 (2009), 254–264.
303. Boeckh, M., Ljungman, P., How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113 (2009), 5711–5719.
304. Zhang, L.-F., Tian, J.-H., Yi, K., Jia, W.-Q., Yang, K.-H., Prophylactic treatment of ganciclovir to prevent and cure cytomegalovirus infection after renal transplantation: a systematic review. Fudan Univ. J. Med. Sci. 37 (2010), 131–139.
305. Tabbara, K.F., Al-Balushi, N., Topical ganciclovir in the treatment of acute herpetic keratitis. Clin. Ophthalmol. 4 (2010), 905–912.
306. Snydman, D.R., Limaye, A.P., Potena, L., Zamora, M.R., Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant. Proc. 43 (2011), S1–S17.
307. Skrzypek, S., Electrode mechanism and voltammetric determination of selected guanido compounds. Cent. Eur. J. Chem. 10 (2012), 977–988.
308. Bedel, A.N., Hemmelgarn, T.S., Kohli, R., Retrospective review of the incidence of cytomegalovirus infection and disease post liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir versus oral valganciclovir. Liver Transpl. 18 (2012), 347–354.
309. Sahin, A., Hamrah, P., Acute herpetic keratitis: what is the role for ganciclovir ophthalmic gel?. Ophthalmol. Eye Dis. 4 (2012), 23–34.
310. Buonsenso, D., Serranti, D., Gargiullo, L., Meccarelli, M., Ranno, O., Valentin, P., Congenital cytomegalovirus infection: current strategies and future perspectives. Eur. Rev. Med. Pharmacol. Sci. 16 (2012), 919–935.
311. Christoforidis, J.B., Chang, S., Jiang, A., Wang, J., Cebulla, C.M., Intravitreal devices for the treatment of vitreous inflammation. Mediators Inflamm., 2012, 2012, 126463 8 pages.
312. Komatsu, T.E., Pikis, A., Naeger, L.K., Harrington, P.R., Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways. Antiviral Res. 101 (2014), 12–25.
313. Minces, L.R., Nguyen, M.H., Mitsani, D., Shields, R.K., Kwak, E.J., Silveira, F.P., Abdel-Massih, R., Pilewski, J.M., Crespo, M.M., Bermudez, C., Bhama, J.K., Toyoda, Y., Clancy, C.J., Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens. Antimicrob. Agents Chemother. 58 (2014), 128–135.
314. Madhusudhana, R.G., Babu, C.J.G., Mani, T.T., Validated analytical method development of ganciclovir: review. Int. J. Pharm. Pharmaceut. Anal. 2 (2016), 7–12.
315. Xiao-bo, W.U., Zhen-yan, L.V., Yong, H.E., A systematic review of ganciclovir combined with intravenous immune globulin in treatment of cytomegalovirus infection in infants. Clin. Med. J. 2 (2016), 31–36.